RESUMO
A double-blind controlled clinical trial of a long-acting isoprenaline preparation-'Saventrine'-is reported in 22 patients. The response to treatment was poor and did not significantly differ from the 22 control patients treated with a placebo. Furthermore, severe palpitations proved a serious limiting factor. Long-term 'Saventrine' therapy is not recommended in the management of severe bronchial asthma (AU)
Assuntos
Humanos , Criança , Adolescente , Adulto , Pessoa de Meia-Idade , Idoso , Masculino , Feminino , Asma/tratamento farmacológico , Isoproterenol/uso terapêutico , Método Duplo-Cego , Isoproterenol/efeitos adversosRESUMO
Adrenaline and Noradrenaline both caused a contraction of the vas deferens. However, adrenaline was a more potent stimulant than noradrenaline. Isoprenaline by itself had no effect on the vas deferens, but it modified the stimulatory effect of subsequent administered adrenaline and noradrenaline. In small doses isoprenaline lessened and in large doses it potentiated the stimulating effect of the other two amines, the degree of inhibition by isoprenaline being greater on noradrenaline than on adrenaline. It was suggested that isoprenaline acted by inhibiting alpha adrenergic receptors in small concentrations, stimulating them in large concentrations and not by stimulating Beta receptors as is presently believed (AU)
